The HPRCC literature often refers to a successful clinical trial of the dual MET/VEGFR2 inhibitor foretinib, which involved 10 patients with germline MET mutations, despite the fact that the clinical development of this drug has been discontinued [143]. This evidence concerns the gene MET and papillary renal cell carcinoma.